In the latest trading session, Celgene closed at $88.30, marking a +1.04% move from the previous day. This move outpaced the S&P 500's daily gain of 0.78%. Elsewhere, the Dow gained 0.95%, while the tech-heavy Nasdaq added 0.98%.
Heading into today, shares of the biotechnology company had lost 3.6% over the past month, lagging the Medical sector's gain of 2.59% and the S&P 500's gain of 2.17% in that time.
Investors will be hoping for strength from CELG as it approaches its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect CELG to post earnings of $2.22 per share. This would mark year-over-year growth of 16.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.81 billion, up 15.8% from the year-ago period.
CELG's full-year Zacks Consensus Estimates are calling for earnings of $8.76 per share and revenue of $15.11 billion. These results would represent year-over-year changes of +17.74% and +16.27%, respectively.
It is also important to note the recent changes to analyst estimates for CELG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note CELG's current valuation metrics, including its Forward P/E ratio of 9.97. This represents a discount compared to its industry's average Forward P/E of 29.03.
Investors should also note that CELG has a PEG ratio of 0.46 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.04 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 99, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Celgene closed at $88.30, marking a +1.04% move from the previous day. This move outpaced the S&P 500's daily gain of 0.78%. Elsewhere, the Dow gained 0.95%, while the tech-heavy Nasdaq added 0.98%.
Heading into today, shares of the biotechnology company had lost 3.6% over the past month, lagging the Medical sector's gain of 2.59% and the S&P 500's gain of 2.17% in that time.
Investors will be hoping for strength from CELG as it approaches its next earnings release, which is expected to be October 25, 2018. In that report, analysts expect CELG to post earnings of $2.22 per share. This would mark year-over-year growth of 16.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.81 billion, up 15.8% from the year-ago period.
CELG's full-year Zacks Consensus Estimates are calling for earnings of $8.76 per share and revenue of $15.11 billion. These results would represent year-over-year changes of +17.74% and +16.27%, respectively.
It is also important to note the recent changes to analyst estimates for CELG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note CELG's current valuation metrics, including its Forward P/E ratio of 9.97. This represents a discount compared to its industry's average Forward P/E of 29.03.
Investors should also note that CELG has a PEG ratio of 0.46 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.04 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 99, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.